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Abstract
The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms
and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects.
This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms
and memory function. A randomised, double-blind crossover design compared the effects of (i) placebo, (ii) THC 8 mg,
(iii) CBD 16 mg and (iv) THC 8 mg+ CBD 16mg administered by inhalation through a vaporiser. Using an experimental
medicine approach to predict treatment sensitivity, we selected 48 cannabis users from the community on the basis of
(1) schizotypal personality questionnaire scores (low, high) and (2) frequency of cannabis use (light, heavy). The Brief
Psychiatric Rating Scale (BPRS), Psychotomimetic States Inventory (PSI), immediate and delayed prose recall (episodic
memory), 1- and 2-back (working memory) were assessed on each day. Results indicated that THC increased overall
scores on the PSI, negative symptoms on BPRS, and robustly impaired episodic and working memory. Co-
administration of CBD did not attenuate these effects. CBD alone reduced PSI scores in light users only. At a ratio of 2:1,
CBD does not attenuate the acute psychotic and memory impairing effects of vaporised THC. Frequent cannabis users
may show a blunted anti- psychotic response to CBD, which is of concern due to the high rates of cannabis use
disorders in patients with schizophrenia.
Introduction
Cannabis (marijuana) is used by over 180 million people
worldwide1. Possible consequences of use include
dependency, cognitive impairment and increased risk of
psychotic illness2. However, most people who try cannabis
do not experience prolonged adverse effects. Several fac-
tors predict vulnerability, including the rs2494732 locus of
the AKT1 genotype3–5, adolescent exposure6,7, frequency
of use8–10, schizotypy or schizophrenia11–15 and the type
of cannabis used2,16. Although it is typically classiﬁed as a
single drug, the cannabis plant can contains over 100
unique ‘cannabinoids’, with diverse and sometimes
opposing pharmacological actions17.
Cannabis containing high levels of delta-9-
tetrahydrocannabinol (THC) and little if any cannabidiol
(CBD) is becoming increasingly prevalent18,19 and is
linked to greater cannabis dependency, memory impair-
ment and paranoia20 and increased risk of psychotic
illness21.
Delta-9-THC produces the effects that users seek from
cannabis, including ‘stoned’, ‘like drug effect’ and ‘want
more drug’22,23. THC elicits robust, dose-dependent
impairments in immediate and delayed verbal
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memory2,24 and transient positive and negative symptoms
reminiscent of schizophrenia25,26.
CBD is non-intoxicating and does not inﬂuence ratings
of ‘stoned’ following the administration of THC or can-
nabis2,16. However, CBD can produce opposite effects to
THC across a range tasks and functional neuroimaging
assessments26–28. In terms of behavioural effects, CBD
given alone was found to improve memory consolida-
tion29 and in combination with THC is associated with
higher recognition memory scores in chronic cannabis
users30. CBD also appeared to block the impairing effects
of THC on verbal recall in a naturalistic study31, which
was replicated in a laboratory study of oral CBD and
intravenous THC32.
In terms of psychosis, CBD displayed equivalent efﬁcacy
to a standard antipsychotic drug for the treatment of
positive and negative symptoms33. A preliminary study
with 6 volunteers found that oral CBD pre-treatment
reduced acute psychotic symptoms following intravenous
THC26. In a subsequent study of 48 volunteers, CBD
reduced the incidence of clinically signiﬁcant positive
psychotic symptoms (but not their overall severity) fol-
lowing intravenous THC32. However, a naturalistic study
did not ﬁnd evidence for protective effects of CBD on
THC-induced psychotic-like symptoms31.
Chronic exposure to CBD has also been linked to fewer
psychotic-like symptoms in those who have been exposed
to THC34, a ﬁnding that was replicated in light but not
heavy cannabis users30.
Taken together, the available data provides some evi-
dence that CBD protects against the harmful effects of
THC on memory and psychotic-like symptoms. However,
only one study has examined the interactive effects of
inhaled THC and CBD35,36 no study to our knowledge has
examined the interactive effects of THC and CBD on
these variables in an experimental design with an inhaled
route of administration37, which better reﬂects how can-
nabis is typically administered than oral or intravenous
routes. Furthermore, preliminary data suggest that fre-
quency of cannabis use and schizotypy may predict how
an individual responds to THC and and/or CBD. How-
ever, we are unaware of any experimental studies com-
paring the effects of different cannabinoid combinations
(e.g. THC, THC+CBD, CBD) among volunteers selected
for their vulnerability or resilience.
Here, we adopted an experimental medicine approach
in order to assess the effects of cannabinoids on
psychotic-like symptoms and memory function. A ran-
domised, double- blind, crossover design was used to
mimic the effects of cannabis with varying cannabinoid
concentrations, as well as CBD alone. Across four ses-
sions, each volunteer received THC (8 mg), THC (8mg)
+CBD (16mg), CBD (16 mg) and placebo (ethanol
vehicle). We predicted, ﬁrstly, that memory impairment
and psychotic-like symptoms would occur following
THC, secondly, CBD would offset these effects when co-
administered with THC, and thirdly, CBD alone would
have pro-cognitive and anti- psychotic effects. In order to
extend previous work showing that schizotypy/psychosis
and cannabis use frequency are possible vulnerability/
resilience factors cannabis users were selected from a
large-scale study on the basis of their cannabis use and
schizotypal personality scores30. We predicted that
infrequent users8–10,30 and people with high psychosis
proneness11,12,14,15 would show heightened susceptibility
to THC, CBD, and their interactive effects.
Methods
Participants
Participants were recruited on the basis of having pre-
viously volunteered in a large scale study of over 400
cannabis users30. Those scoring in the top and bottom
quartiles of (1) Schizotypal Personality Questionnaire
score (low, high) were invited to take part, from this group
we set out to recruit 24 light (1–24 days per month) and
24 heavy (25+ days per month) cannabis users. Addi-
tional data from this study on facial affect recognition and
effects on a visual analogue scale have been reported
elsewhere38.
Subjects were matched for age and estimated premorbid
verbal intelligence (as measured by the Spot the Word
task39) across heavy and light users. Inclusion criteria
were: (i) self-reported abstinence from cannabis, other
drugs and alcohol use for 24 h prior to each test day; (ii)
ﬂuent in English, (iii) normal or corrected to normal
vision.
Exclusion criteria were: current self-reported (i)
respiratory health problems or physical health problems,
(ii) pregnancy or the risk of being pregnant, (iii) clinically
diagnosed learning impairments, (iv) clinically diagnosed
schizophrenia/psychosis or substance abuse problems and
(v) no illicit drug use other than cannabis more than once
a week.
Design
A four session, randomised, double-blind crossover
design was used to compare the acute effects of THC
(8 mg), CBD (16 mg) and their combination (8 mg THC
+ 16mg CBD) with placebo (ethanol vehicle). Both can-
nabinoids were formulated in alcohol solution and were
purchased from STI Pharmaceuticals (Brentwood, Essex,
UK). A total of 48 volunteers completed the study, com-
prised equally from the following groups: low schizotypy,
light cannabis users (LS-L); low schizotypy, heavy users
(LS-H); high schizotypy, light users (HS-L); high schizo-
typy, heavy users (HS-H). N= 12 per experimental group
was chosen to detect THC-induced (compared to pla-
cebo) impairment in memory at a power of 0.8322.
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Treatment order across the 4 sessions was determined by
a balanced Latin square.
Procedure
Experimental sessions occurred on four occasions each
separated by a one-week wash-out to minimise carry-over
effects ( > 3 times elimination half-life of THC25). We
used urine and saliva screens to verify drug use. Partici-
pants completed baseline assessments before, and then
commencing 10min after drug administration. The full
test battery took approximately 1.5 h on each test day.
Participants were reimbursed £120 for their time on the
last testing day and debriefed fully. All participants pro-
vided written, informed consent on each occasion and
ethical approval was given by the UCL Research Ethics
Committee.
Drug administration
Cannabinoids and placebo (ethanol vehicle) were
administered using a Volcano Medic Vaporisor (Storz &
Bickel, Tuttlingen, Germany). 8 mg THC dissolved in
ethanol and 16 mg of CBD dissolved in ethanol38 were
administered on a 10-s inhalation cycle wherein partici-
pants was instructed to ﬁrst fully exhale, next fully inhale
from the balloon, hold their breath for 10 s and then fully
exhale; this was repeated until the balloon was empty40.
This inhaled dose of THC has been found to produce
effects on human brain and behaviour, including
psychotic-like symptoms and memory impairment7,40,41.
The 2:1 ratio of CBD:THC reﬂects the upper limit (mean
+ 3 SD) found in high CBD/low THC cannabis prepara-
tions42. Participants were given a test balloon to famil-
iarise themselves with the procedure before any drug
administration occurred. The balloon was ﬁlled, covered
with an opaque bag, and administered by an independent
researcher so that the experimenter collecting behavioural
data and participant was blind to drug condition.
Assessments
Before drug administration participants completed the
Beck Depression Inventory43, Spielberger Trait Anxiety
Inventory44, Schizotypal Proneness Questionnaire45 and
Spot the Word Test39. After drug administration, the 48-
item Psychotomimetic States Inventory46 was used to
assess acute schizotypal symptoms. It has subscales of
perceptual distortion, cognitive disorganisation, anhedo-
nia, mania, paranoia and delusionary thinking. Each item
is rated from 0 (not at all) to 3 (strongly) on statements
describing current experiences. Current psychiatric
symptoms were assessed with the experimenter-rated
Brief Psychiatric Rating Scale47 rated from 0 (not present)
to 7 (extremely severe) with subscales of positive symp-
toms and negative symptoms. Participants also completed
cognitive measures post-drug administration.
Cognitive measures
Prose recall
Verbal memory was assessed using immediate and
delayed prose recall48. Participants were required to recall
a short passage of prose (30 s news bulletin) immediately
and after a 20 min delay ﬁlled with other assessments. 4
versions of the prose recall were administered in a
counterbalanced order.
N-back
This task taps spatial working memory with an
increasing load. It has previously shown sensitivity to
acute49 and chronic50 drug effects. The participant was
presented with a symbol (smiley face) in one of six spatial
locations. A ﬁxation cross remained in the centre of the
screen throughout the task. When the next face appeared,
they were required to indicate whether it was in the same
location as the previous face in the 1- back version of the
task, or the same location as the face two positions before
(2-back). Each block consisted of 25 “match” and 25 “no-
match” trials in random order, i.e. 50 trials in total, pre-
ceded by ten practice trials. All symbols were presented
5 cm from the ﬁxation cross. Each symbol was presented
for 300ms with an inter-stimulus interval (ISI) of
450msec. Versions were randomised across testing days.
Fluency (57)
To assess phonological and sematic ﬂuency respectively,
participants were asked to generate as many words as
possible in 60 s starting with a pre-determined letter, or
exemplars related to a pre-determined category. On each
testing day participants generated exemplars of one letter
and one category.
Reitan’s trailmaking test (TMT: 59)
Processing speed was measured using the TMT (Form
A and B). Form A requires participants to connect 25
numbers in an ascending numerical sequence. Form B
requires participants to connect 13 numbers (1–13) and
12 letters (A-L) in an ascending number-letter sequence.
The dependent variable is time to complete the task, and
then the time to complete the B form subtracting the
basic psychomotor speed (B-A).
Statistical analysis
Data were analysed using IBM SPSS version 20.
Demographics and scores on questionnaires were ana-
lysed using repeated measures ANOVAs with two
between-subjects variables (frequency of use, schizotypy).
Assumptions of parametric tests were examined and
data were transformed where they were not normally
distributed, however in practice this did not alter the
outcome so the of the analyses of the untransformed data
are reported. Drug was entered as a within subjects factor,
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and was coded as a simple contrast (Placebo versus THC,
Placebo versus THC+CBD, Placebo versus CBD).
Additional within subjects factors were added where
appropriate (Subscale for the Psychotomimetic States
Inventory and Brief Psychiatric Rating Scale, Delay for
prose recall, Load for N-back). Interactions with Drug
were explored using simple contrasts. Interactions
between other factors in repeated measures ANOVA
models were analysed using pairwise comparisons with a
local Bonferroni correction. Pearson correlational ana-
lyses were performed to explore the impact of frequency
of cannabis use on any drug effects, and were also
Bonferroni-corrected. All statistical tests were two-tailed
and p values are displayed uncorrected in the text.
Results
Group characteristics
As shown in Table 1, groups did not differ in age
(F(3,44)= 2.540, p= 0.069), gender (X
2
(3)= 4.437, p=
0.218), years of education (F(3,44)= 1.575, p= 0.209),
scores on the spot the word task (F(3,44)= 0.802, p=
0.499), last use of cannabis (F(3,44)= 1.223, p= 0.313), or
number of years cannabis had been used (F(3,44)= 0.666,
p= 0.578). BDI scores were missing for two participants
(heavy user, low schizotypy group) and were replaced
with the group mean. There was a main effect of schi-
zotypy on scores on the SPQ (F(1,44)= 12.473, p=
0.001), BDI (F(1,44)= 14.989, p < 0.001) and STAI (F(1,44)
= 9.054, p= 0.004) where the high schizotypy group had
higher scores than the low schizotypy group for each
measure. Light and heavy users of cannabis differed on
the time to smoke a standard quantity of cannabis sold
in the UK (3.5 g; 1/8 oz) (F(1,44)= 8.539, p= 0.005) and
on the number of days per month they used cannabis
(F(1,44)= 32.295, p < 0.001) where heavy users smoked
3.5 g in fewer days, and used cannabis on more days per
month than light users. There were no differences in the
number of people who had used tobacco (X2(3)= 4.457,
p= 0.208), days since last use of tobacco (F(3,33)= 0.592,
p= 0.625), years of tobacco use (F(3,31)= 0.352, p=
0.788), or days per month of tobacco use (F(3,31)= 0.688,
p= 0.566). For alcohol, no differences were found for
years used (F(3,44)= 0.207, p= 0.891) or days per month
of use (F(3,44)= 0.693, p= 0.561).
Table 1 Means (SD) for demographic, mental health, and drug use variables for light and heavy cannabis users
Light Heavy
Low schizotypy High schizotypy Low schizotypy High schizotypy
Age 21.00 (2.13) 22.90 (2.02) 21.42 (1.62) 21.5 (1.38)
Gender ratio (m:f) 9:3 7:5 11:1 7:5
Education (years) 15.75 (1.22) 15.79 (1.30) 15.04 (1.77) 14.5 (2.31)
BDI-11 3.25 (3.91) 7.67 (7.10) 3.00 (1.70) 15.75 (12.96)
SPQ 9.25 (12.66) 22.83 (11.84) 10.58 (7.07) 22.8 (17.07)
STAI 35.67 (10.29) 41.67 (8.19) 33.00 (6.63) 42.58 (10.25)
Spot the word task 51.17 (5.13) 49.75 (4.37) 51.42 (4.89) 48.75 (4.94)
Cannabis (N) 12 12 12 12
Cannabis used (years) 5.88 (3.48) 6.91 (3.00) 5.92 (2.15) 5.33 (2.39)
Cannabis use (days/month) 11.92 (6.84) 11.71 (10.24) 24.38 (9.06) 26.00 (5.64)
Days since last use 2.50 (1.38) 13.83 (33.64) 4.66 (8.15) 1.92 (0.79)
Time to smoke 3.5 g (days) 11.50 (15.83) 20.54 (16.13) 7.52 (8.84) 3.92 (2.75)
Alcohol (N) 12 12 12 12
Alcohol used (years) 6.04 (2.18) 6.71 (2.66) 6.5 (2.19) 5.25 (7.85)
Alcohol (days/month) 11.54 (5.66) 8.04 (4.87) 10.00 (7.67) 11.12 (7.43)
Tobacco (N) 6 9 10 9
Tobacco used (years) 4.57 (1.90) 5.22 (2.54) 5.5 (2.37) 5.83 (3.02)
Tobacco (days/month) 20.00 (11.40) 22.45 (12.16) 23.8 (10.89) 27.56 (7.33)
Tobacco cigarettes/day 6.66 (3.77) 6.39 (3.12) 8.55 (5.31) 9.22 (4.47)
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Psychotomimetic states inventory (PSI)
There was a main effect of Drug (F(2,105)= 5.550, p=
0.003, ŋp
2= 0.112), driven by increased scores relative to
placebo for THC (p= 0.014) and THC+CBD (p= 0.022)
but no change following CBD (p= 0.544).
An interaction between Drug and Subscale was found
(F(6,267)= 4.881, p < 0.001, ŋp
2= 0.100) reﬂecting
increased scores following THC and THC+CBD com-
pared to placebo for the subscales of ‘Perceptual Distor-
tion’ (THC: p= 0.006; THC+CBD: p= 0.005; Fig. 1b)
and ‘Cognitive Disorganisation’ (THC: p= 0.008; THC+
CBD: p= 0.004; Fig. 1c). CBD did not elicit change rela-
tive to placebo for any of these individual subscales, and
no drug effects were found for the remaining subscales of
‘Anhedonia’, ‘Delusory Thinking’, ‘Mania’ and ‘Paranoia’
(Fig. 1).
There was also an interaction between Drug and Fre-
quency of use (F(2,105)= 3.582, p= 0.024, ŋp
2= 0.075).
Exploration of the interaction showed that light and heavy
users had similar responses to THC (p= 0.504) and THC
+CBD (p= 0.977) relative to placebo, but reacted dif-
ferently to CBD (p= 0.005). As shown in Fig. 2,
CBD reduced PSI scores relative to placebo in light users
(p= 0.015), but not in heavy users (p= 0.104) as shown in
Fig. 2.
Additionally, there was a Schizotypy by Subscale inter-
action (F(3,150)= 6.856, p < 0.001, ŋp
2= 0.135), as shown
in Table 2. Across all drug sessions, high schizotypy
volunteers experienced greater PSI scores for ‘Anhedonia’
(p < 0.001), ‘Cognitive Disorganisation’ (p= 0.001),
‘Mania’ (p= 0.004), and ‘Paranoia’ (p= 0.007) relative to
Fig. 1 Effects of THC and CBD alone and in combination, along with placebo, across the whole sample on subscales of psychotomimetic
symptoms (PSI). THC and THC+ CBD increased perceptual distortions (b) and cognitive disorganisation (c) but not other subscales (a; d; e; f).
THC= T (Black shading), THC+ CBD= T (grey shading), CBD= C, Placebo= P
Fig. 2 Analysis of effects of THC, CBD, the combination and placebo in
low frequency (light) and high frequency (heavy) cannabis users on
total psychotomimetic symptom scores
Morgan et al. Translational Psychiatry  (2018) 8:181 Page 5 of 10
those with low schizotypy, but no differences were found
for ‘Delusory Thinking’ or ‘Perceptual Distortion’.
Signiﬁcant main effects were found for the factors of
Subscale (F(3,150)= 80.254, p < 0.001, ŋp
2= 0.646) and
Schizotypy (F(1,44)= 15.271, p < 0.001, ŋp
2= 0.258).
Brief psychiatric rating scale (BPRS)
There was no main effect of Drug. An interaction
between Drug and Subscale was found (F(3,132)= 3.396,
p= 0.020, ŋp
2= 0.072) as well as a main effect of Subscale,
reﬂecting higher scores for Positive relative to Negative
items on the BPRS (F(1,44)= 122.149, p < 0.001, ŋp
2=
0.735). There were no other signiﬁcant effects or inter-
actions. Exploration of the Drug by Subscale interaction
revealed that for Positive items, cannabinoid administra-
tion had no effects, but for Negative items both THC (p=
0.025) and THC+CBD (p= 0.008) increased scores
relative to placebo (Fig. 3).
Prose recall
There was a main effect of Drug (F(3,132)= 4.458, p=
0.005, ŋp
2= 0.092) which was driven by impairments
following THC (p= 0.031) and THC+CBD (p= 0.024)
relative to placebo, whilst CBD had no effect (Fig. 4). A
main effect of Delay was also found, reﬂecting poorer
recall at delayed compared to immediate recall (F(1,44)=
47.794, p < 0.001, ŋp
2= 0.521).
Spatial N-back
There was also a main effect of Drug (F(3,129)= 3.421, p
= 0.019, ŋp
2= 0.074), due to a reduction in sensitivity
following THC (p= 0.012) and THC+CBD (p= 0.020)
compared to placebo, but no differences for CBD (p=
0.532), Fig. 5a. Data for was excluded for one participant
on the 1-back task due to an excessively high rate of
incorrect responses (69%; chance level: 50%), suggesting
they had misunderstood the task instructions. Analysis of
d’ scores revealed a main effect of Load (F(1,43)= 16.818, p
< 0.001, ŋp
2= 0.281), attributable to higher d’ (sensitivity)
on the 1-back compared to the 2-back task (Fig. 5a).
Analysis of RTs on correct trials revealed a main effect of
Load (F(1,43)= 18.951, p < 0.001, ŋp
2= 0.306), due to faster
responses on the 1-back compared to the 2-back task (Fig.
5b) but no effect of Drug.
Fluency
Analysis of exemplars produced on the semantic ﬂu-
ency task revealed a signiﬁcant effect of Drug (F(3,132)=
6.029, p= 0.001, ŋp
2= 0.121) which was driven by
higher scores following THC+ CBD (M:19.00, SE:
0.546) compared to placebo (M:16.63, SE: 0.655) (p=
0.005) but no differences for THC (M: 17.2 SE:0.68) or
CBD (M:14.3 SE:. 0.34) No signiﬁcant effects emerged
for the number of exemplars produced, or errors, on
phonological ﬂuency. No effects were found for
semantic ﬂuency errors.
Table 2 Estimated marginal means and standard error
(SE) for the Schizotypy by Subscale interaction on the
Psychotomimetic States Inventory (PSI), collapsed acrosss
drug conditions
High
schizotypy
Low
schizotypy
M SE M SE
Delusionary thinking 1.42 0.28 0.59 0.28
Perceptual distortion 1.48 0.30 1.10 0.30
Cognitive disorganisation 7.81 0.73 4.03 0.73
Anhedonia 6.37 0.50 3.48 0.50
Mania 4.77 0.40 3.05 0.40
Paranoia 1.85 0.39 0.27 0.39
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Fig. 3 Effects of THC, CBD, the combination and placebo on positive
and negative symptoms on the Brief Psychiatric Rating Scale
Fig. 4 Effects of THC, CBD, the combination and placebo on episodic
memory on the prose recall task
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Retain’s trailmaking test
For part A, a signiﬁcant effect of Drug was found
(F(3,132)= 4.211, p= 0.013, ŋp
2= 0.087). This was driven
by faster completion following CBD (M: 14.20, SE: 0.47)
compared to placebo (M: 15.76, SE: .76) (p= 0.045) but
no differences for THC or THC+CBD. No signiﬁcant
effects were found for part B, or for part B-part A.
Correlations
Since the effects of CBD on the PSI were moderated by
frequency of cannabis use, correlations were carried out
between the effects of CBD on total PSI scores (CBD –
placebo) and indices of cannabis use (days of cannabis use
per month, years of cannabis used) separately in light
(n= 24) and heavy users (n= 24). No correlations were
found in light users. In heavy users, a trend for a positive
correlation emerged for years of cannabis use (r= 0.434,
p= 0.034) indicating that a longer history of cannabis use
was associated with blunted antipsychotic effects of CBD.
Discussion
The main ﬁndings of this study were an increase in
psychotomimetic symptoms following administration of
both THC alone and the combination of THC+CBD.
Administration of both THC and the combination (THC
+CBD) increased negative symptoms on the BPRS, along
with perceptual distortions and cognitive disorganisation
on the PSI. Lower frequency cannabis users experienced a
reduction in psychotomimetic symptoms following CBD
alone compared with placebo. Both THC and THC+
CBD impaired performance on episodic and working
memory tasks. Contrary to hypotheses, CBD did not offset
the psychotomimetic effects of THC.
In line with previous studies, we found that THC in the
laboratory at a dose of 8 mg inhaled in a Volcano
vaporiser increased some psychotic-like symptoms7,40.
Contrary to predictions, CBD when given concurrently
with THC in a 2:1 ratio had no impact on psychotomi-
metic symptoms, which were still higher than placebo or
CBD alone. It has previously been suggested that CBD
may ameliorate the harmful effects of THC on psychotic-
like symptoms51 which has been supported by some
empirical evidence27,30,32 including two experimental
studies (n= 6 in a crossover27 and n= 48 in parallel
groups32). The latter study32 found a reduction in positive
psychotic symptoms following intravenous THC, which
did not reach signiﬁcance following pre-treatment of oral
CBD. However, a signiﬁcant protective effects of CBD was
found when the authors compared the number of people
who met clinically signiﬁcant psychosis (an increase from
baseline of ≥3 points15). It may be the case therefore, that
CBD is only protective when THC induces a strong psy-
chotic reaction, which might be achieved by using higher
doses of THC. In the current study, although THC
increased scores on the PSI (perceptual distortion and
cognitive disorganisation) and BPRS negative symptoms,
it did not increase BPRS positive or PSI paranoia scores at
a group level. This in itself is interesting as the same dose
and administration route used here has been reliably
shown to increase these symptoms in other studies (e.g.,
ref. 40), possible reasons maybe repeating each of these
measures in this four-way crossover design. Additionally
both our groups were heavier cannabis users than pre-
vious studies which have administered similar doses in the
lab and tolerance to psychotomimetic effects has been
previously shown (D’Souza et al., 2005). Another impor-
tant consideration is that it is unclear which CBD:THC
ratio is most effective for reducing harm16. In this study
doses of 8 mg THC and 16mg CBD were chosen to create
a CBD:THC ratio of 2:1, reﬂecting the upper limit (mean
+ 3 SD) found in high CBD/low THC cannabis prepara-
tions42. In addition, Englund et al. pre-treated volunteers
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with oral CBD (600mg) and before intravenous THC
(1.5 mg/kg). These very different doses and routes of
administration (which inﬂuence absorption and metabo-
lite proﬁles52) may account for our divergent ﬁndings. In
street cannabis, ﬁndings from our own lab did not suggest
an acute protective effect of CBD against the psychoto-
mimetic effects of THC31 but rather a chronic effect,
related to levels in hair30,51, which is in accordance with
the ﬁndings of this current study.
Similarly with cognition, impairments to working and
episodic memory were observed following both adminis-
tration THC and the combination of THC+CBD. Con-
trary to our predictions, CBD did not offset the effects of
THC. This differs from our naturalistic ﬁndings where
users smoking cannabis with higher levels of CBD resul-
ted in less impairment than those with lower levels31. One
reason for this difference from naturalistic ﬁndings could
be other chemicals present in whole plant cannabis
material, including terpenes53, which do not occur in our
synthetically produced cannabinoids. However, inter-
active effects of CBD and THC on memory function were
also reported by Englund et al. in a controlled study of
synthetic oral CBD and intravenous THC32. Moreover, in
the current data we also found that CBD improved facial
affect recognition when administered alone, and offset
impairments on the same task when co-administered with
THC38. It is worth noting that the protective effects in
CBD that study were of a small effect size, and limited to a
single intensity of facial stimuli (40%)38. Moreover, CBD
was not protective of immediate verbal recall in Englund
et al.32, and although it showed evidence for a protective
effect on delayed recall, these were not supported by a
signiﬁcant condition by group interaction. Thus, taken
together, the ability of CBD to protect against THC-
induced cognitive impairment may be of a small effect
size, and/or inﬂuenced by vulnerability factors which have
not been considered in research studies to date.
One interesting and unexpected ﬁnding was of the
greater number of correct exemplars generated following
THC+CBD than placebo, but no differences between
placebo and THC alone and CBD alone. This is partly in
line with previous ﬁndings with cannabis users54 of
increases in divergent thinking following acute cannabis
use. This increase occurred only in the group given CBD
alongside THC, one possible tentative explanation is that
CBD’s pro-cognitive effects combine with the ability of
THC to stimulate novel thinking to result in successful
task performance.
In this study, no tolerance to the cognitively impairing
or psychotomimetic effects of THC was observed for high
compared to low frequency users which contrasts with
previous studies8–10. Differences between these studies
could be attributable to dose and/or route of adminis-
tration (e.g. smoked or intravenous versus vaporised).
Additionally, previous studies suggesting tolerance
develops to the acute cognitive impairing effects of THC
have generally been small-scale. However, our ﬁndings are
consistent with a recent study which like ours, used
inhalation of THC via a volcano vaporiser60. This was a
large-scale, cross-over study with 122 participants ranging
from daily cannabis users to very infrequent users (as low
as once in the last 3 months). Like our present data, they
found no evidence of tolerance to the impairing effects of
acute THC on neurocognitive function.
Our rationale for including users high and low in
schizotypy was that those high in schizotypy may be more
vulnerable to the pro-psychotic effects of THC11–14.
however this hypothesis was not borne out in the data.
Additionally we saw no evidence of tolerance to the
psychotomimetic effects when THC was administered in
this manner in the lab to heavy cannabis users, when
compared to lower frequency users, in contrast to pre-
vious ﬁndings8. There may be a variety of reasons for this,
including the fact that the current study used a relatively
low dose of THC (8 mg) compared to doses estimated in
naturalistic studies (~35 mg in the UK42; ~32mg in the
Netherlands60). The inhalation procedure was standar-
dised, with the aim of controling for dose titration that
may occur with cannabis smokers in a naturalistic set-
ting42,60. Previous studies investigating associations
between schizotypy and acute psychotomimetic effects of
cananbis/THC have used naturalistic designs11,12 or ret-
rosepctive reports of drug effects13,14. It is therefore
possible that differences in dose, smoking behaviour and
expectancy/recall may have inﬂuenced these ﬁndings to
some extent. A controlled study15 reported similar psy-
chotomimetic effects of THC in people diagnosed with
schizophrenia and controls.
An interesting ﬁnding to emerge from this research was
that CBD alone reduced baseline levels of psychotomi-
metic symptoms in light but not heavy users. Moreover,
we found a trend level correlation in heavy users, sug-
gesting that the antipsychotic effects of CBD were
increasingly blunted as years of cannabis use increased.
This ﬁnding is broadly consistent with our previous
ﬁnding that CBD in hair was associated with fewer
psychotic-like symptoms in light but not heavy users30.
This relates to recent work suggesting that CBD may be a
potential treatment in schizophrenia through boosting
brain levels of anandamide33. Crucially, that study exclu-
ded patients with a positive urine screen for cannanabi-
noids, which might have inﬂuenced their antipsychotic
response to CBD. The effect of CBD observed in this
study was conﬁned only to low frequency users, sug-
gesting a potential tolerance to these effects in higher
frequency users, which may have implications for the
future use of this compound in the treatment of schizo-
phrenia, which is highly co-morbid with cannabis use
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disorders60. However, further research with repeated
dosing of CBD in patients would be needed to support or
refute this possibility. Neurobiologically, that these effects
were conﬁned to low frequency users ﬁts with research
suggesting that high frequency cannabis users have a
reduction in anandamide60, potentially as a result of
chronic cannabis use, which may mean their endo-
cannabinoid systems are less sensitive to exogenous can-
nabinoids. In addition, a subtle pro-cognitive effect of
CBD was observed on the trailmaking task, but only as an
increase in psychomotor speed, without any impact on
cognitive ﬂexibility, hence this ﬁnding should be treated
with caution.
This study has several strengths; it used a large sample
size in a four-way cross-over in a highly controlled
laboratory setting and the use of well-validated tasks. The
Volcano
Vaporiser method of administering cannabinoids pro-
duces similar plasma and pulmonal THC levels in com-
parison to smoked cannabis cigarettes59,60 and delivers
between 80% of the loaded THC35,36. Limitations of the
current study include not having plasma measures of
THC and CBD, therefore we were not able to accurately
verify our controlled inhalation procedure, although it has
been veriﬁed in previous research40.
In summary, our study replicated previous ﬁndings of a
pro-psychotic effect of THC for some psychotic symp-
toms e.g. negative symptoms, cognitive disorganisation
and perceptual distortions and extended these to include
a similar effect of a combination when given in a 2:1 ratio
(CBD: THC). Cognitive impairments were evident fol-
lowing THC and the combination but no cognitive
impairments were observed following CBD alone. CBD
was able reduce sub-clinical psychotic-like symptoms in
low frequency cannabis users, but not in those using the
drug more heavily. This highlights a potentially important
area of further research, given the therepeutic potential of
CBD for psychosis and the high incidence of cannabis use
disorders in this population.
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